108 related articles for article (PubMed ID: 8180329)
1. Clivarin and other LMWHs in an ex vivo cardiopulmonary bypass model. Studies on contact activation.
Heller W; Wendel HP
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S45-54. PubMed ID: 8180329
[TBL] [Abstract][Full Text] [Related]
2. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
3. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation.
Gikakis N; Khan MM; Hiramatsu Y; Gorman JH; Hack CE; Sun L; Rao AK; Niewiarowski S; Colman RW; Edmunds LH
Circulation; 1996 Nov; 94(9 Suppl):II341-6. PubMed ID: 8901772
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood.
Konstantinidis K; Gerasimidis T; Verdy E; Elalamy I; Samama MM; Gerotziafas GT
Thromb Haemost; 2007 Jan; 97(1):109-18. PubMed ID: 17200777
[TBL] [Abstract][Full Text] [Related]
5. Influence of low molecular weight heparin preparations on human internal thoracic artery contraction.
Buzun L; Kleszczewski T; Kostrzewska A; Lisowski P; Oleksza P; Jackowski R; Pedzińska A; Hirnle T
Eur J Cardiothorac Surg; 2004 Nov; 26(5):951-5. PubMed ID: 15519188
[TBL] [Abstract][Full Text] [Related]
6. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
[TBL] [Abstract][Full Text] [Related]
7. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin.
Stief TW
Blood Coagul Fibrinolysis; 2006 Nov; 17(8):633-7. PubMed ID: 17102649
[TBL] [Abstract][Full Text] [Related]
10. Reduction of blood activation in patients receiving aprotinin during cardiopulmonary bypass for coronary artery surgery.
Baufreton C; Velthuis HT; Jansen PG; Besnerais PL; Wildevuur CH; Loisance DY
ASAIO J; 1996; 42(5):M417-23. PubMed ID: 8944919
[TBL] [Abstract][Full Text] [Related]
11. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.
Chan AK; Leaker M; Burrows FA; Williams WG; Gruenwald CE; Whyte L; Adams M; Brooker LA; Adams H; Mitchell L; Andrew M
Thromb Haemost; 1997 Feb; 77(2):270-7. PubMed ID: 9157580
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of plasma kallikrein-kinin system inhibitors from salivary glands of the blood-sucking insect Triatoma infestans.
Isawa H; Orito Y; Jingushi N; Iwanaga S; Morita A; Chinzei Y; Yuda M
FEBS J; 2007 Aug; 274(16):4271-86. PubMed ID: 17645545
[TBL] [Abstract][Full Text] [Related]
13. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
14. In vitro anticoagulation monitoring of low-molecular-weight heparin.
Wang JQ; Shi XB; Yang JG; Hu DY
Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
[TBL] [Abstract][Full Text] [Related]
15. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis.
Durand E; Helley D; Al Haj Zen A; Dujols C; Bruneval P; Colliec-Jouault S; Fischer AM; Lafont A
J Vasc Res; 2008; 45(6):529-37. PubMed ID: 18463418
[TBL] [Abstract][Full Text] [Related]
16. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo model of hemodialysis membrane biocompatibility.
Spencer PC; Schmidt B; Samtleben W; Bosch T; Gurland HJ
Trans Am Soc Artif Intern Organs; 1985; 31():495-8. PubMed ID: 3879781
[No Abstract] [Full Text] [Related]
18. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins.
Mauron T; Lämmle B; Wuillemin WA
Thromb Haemost; 1998 Jul; 80(1):82-6. PubMed ID: 9684790
[TBL] [Abstract][Full Text] [Related]
19. The effect of oral contraceptives and exercise on hemostatic and fibrinolytic mechanisms in trained women.
Huisveld IA; Hospers JE; Bernink MJ; Erich WB; Bouma BN
Int J Sports Med; 1983 May; 4(2):97-103. PubMed ID: 6874180
[No Abstract] [Full Text] [Related]
20. [Biological effects and the mechanism of complement activation--interaction among complement, coagulation, fibrinolysis and kinin generation system].
Kondo M; Takemura S
Nihon Rinsho; 1979 May; 37(5):1038-43. PubMed ID: 381718
[No Abstract] [Full Text] [Related]
[Next] [New Search]
